The TECNIS Odyssey IOL addresses a significant unmet need for cataract patients seeking greater spectacle independence., Bizz ...

The Tecnis PureSee IOL is the first FDA-approved extended depth of focus IOL maintaining contrast sensitivity comparable to ...

Omeros reported positive data from the second of its two pivotal Phase 3 clinical trials evaluating OMS302 in patients undergoing intraocular lens replacement surgery. This multicenter, double-blind, ...

Omeros announced that the company submitted a New Drug Application (NDA) to the FDA for approval of OMS302 for use in patients undergoing intraocular lens replacement (ILR) surgery. OMS302, added to ...

The new, full-range TECNIS Odyssey intraocular lens aims to reduce dependence on glasses, with strong performance in any ...

Johnson & Johnson’s TECNIS Odyssey IOL launched in India, offering a full visual range and high contrast to reduce spectacle ...

-- Submission of New Drug Application Planned for First Half of 2013-- -- Company to Host Conference Call Today at 9:00 a.m. EST-- SEATTLE, Nov. 5, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: ...

Intraocular lenses (IOLs), implanted in the eye as treatment for cataracts or myopia, are a growing global market in an ageing population, one estimated to be worth more than $4.5 billion by 2022.

(Reuters Health) - Seniors who get new lenses implanted during cataract surgery may not only see better but also experience better sleep, suggests a new study of how light entering the eye regulates ...

Enhancement coverage applies within 24 months of the original procedure for refractive and premium lens pathways. Beyond this ...

The TECNIS PureSee IOL addresses both cataract-related vision loss and presbyopia, which affects near vision as eyes age.